カテゴリ： 世界, 医療/バイオ, Market Monitor Global

最小残存病変（MRD）検査のグローバル市場展望 2023年-2029年：フローサイトメトリー、ポリメラーゼ連鎖反応、次世代シーケンシング、リキッドバイオプシー

■ 英語タイトル：Minimal Residual Disease (MRD) Testing Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC12397）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC12397
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：63
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[最小残存病変（MRD）検査のグローバル市場展望 2023年-2029年：フローサイトメトリー、ポリメラーゼ連鎖反応、次世代シーケンシング、リキッドバイオプシー]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の最小残存病変（MRD）検査市場規模と予測を収録しています。・世界の最小残存病変（MRD）検査市場：売上、2018年-2023年、2024年-2029年
・世界の最小残存病変（MRD）検査市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の最小残存病変（MRD）検査市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「フローサイトメトリー」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

最小残存病変（MRD）検査のグローバル主要企業は、Sysmex Corporation、 Natera、 Asuragen、 Quest Diagnostics、 Mission Bio、 LabCorp、 Guardant Health、 NeoGenomics Laboratories、 ARUP Laboratories、 NeoGenomics , Inc、 Opko Health、 Bio-Rad Laboratoriesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、最小残存病変（MRD）検査のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の最小残存病変（MRD）検査市場：タイプ別、2018年-2023年、2024年-2029年
世界の最小残存病変（MRD）検査市場：タイプ別市場シェア、2022年
・フローサイトメトリー、ポリメラーゼ連鎖反応、次世代シーケンシング、リキッドバイオプシー

世界の最小残存病変（MRD）検査市場：用途別、2018年-2023年、2024年-2029年
世界の最小残存病変（MRD）検査市場：用途別市場シェア、2022年
・専門診療所、病院、研究機関

世界の最小残存病変（MRD）検査市場：地域・国別、2018年-2023年、2024年-2029年
世界の最小残存病変（MRD）検査市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における最小残存病変（MRD）検査のグローバル売上、2018年-2023年
・主要企業における最小残存病変（MRD）検査のグローバル売上シェア、2022年
・主要企業における最小残存病変（MRD）検査のグローバル販売量、2018年-2023年
・主要企業における最小残存病変（MRD）検査のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Sysmex Corporation、 Natera、 Asuragen、 Quest Diagnostics、 Mission Bio、 LabCorp、 Guardant Health、 NeoGenomics Laboratories、 ARUP Laboratories、 NeoGenomics , Inc、 Opko Health、 Bio-Rad Laboratories

*************************************************************

・調査・分析レポートの概要
最小残存病変（MRD）検査市場の定義
市場セグメント
世界の最小残存病変（MRD）検査市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の最小残存病変（MRD）検査市場規模
世界の最小残存病変（MRD）検査市場規模：2022年 VS 2029年
世界の最小残存病変（MRD）検査市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの最小残存病変（MRD）検査の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の最小残存病変（MRD）検査製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：フローサイトメトリー、ポリメラーゼ連鎖反応、次世代シーケンシング、リキッドバイオプシー
最小残存病変（MRD）検査のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：専門診療所、病院、研究機関
最小残存病変（MRD）検査の用途別グローバル売上・予測

・地域別市場分析
地域別最小残存病変（MRD）検査市場規模 2022年と2029年
地域別最小残存病変（MRD）検査売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Sysmex Corporation、 Natera、 Asuragen、 Quest Diagnostics、 Mission Bio、 LabCorp、 Guardant Health、 NeoGenomics Laboratories、 ARUP Laboratories、 NeoGenomics , Inc、 Opko Health、 Bio-Rad Laboratories
...

This research report provides a comprehensive analysis of the Minimal Residual Disease (MRD) Testing market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Minimal Residual Disease (MRD) Testing market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Minimal Residual Disease (MRD) Testing, challenges faced by the industry, and potential opportunities for market players.
The global Minimal Residual Disease (MRD) Testing market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Minimal Residual Disease (MRD) Testing market presents opportunities for various stakeholders, including Specialty Clinics, Hospitals. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Minimal Residual Disease (MRD) Testing market. Additionally, the growing consumer demand present avenues for market expansion.
The global Minimal Residual Disease (MRD) Testing market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Minimal Residual Disease (MRD) Testing market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Minimal Residual Disease (MRD) Testing market.
Market Overview: The report provides a comprehensive overview of the Minimal Residual Disease (MRD) Testing market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Flow Cytometry, Polymerase Chain Reaction), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Minimal Residual Disease (MRD) Testing market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Minimal Residual Disease (MRD) Testing market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Minimal Residual Disease (MRD) Testing market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Minimal Residual Disease (MRD) Testing market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Minimal Residual Disease (MRD) Testing market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Minimal Residual Disease (MRD) Testing market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Minimal Residual Disease (MRD) Testing, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Minimal Residual Disease (MRD) Testing market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Minimal Residual Disease (MRD) Testing market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Flow Cytometry
Polymerase Chain Reaction
Next-generation Sequencing
Liquid Biopsies
Market segment by Application
Specialty Clinics
Hospitals
Research Institutions
Global Minimal Residual Disease (MRD) Testing Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sysmex Corporation
Natera
Asuragen
Quest Diagnostics
Mission Bio
LabCorp
Guardant Health
NeoGenomics Laboratories
ARUP Laboratories
NeoGenomics , Inc
Opko Health
Bio-Rad Laboratories
Outline of Major Chapters:
Chapter 1: Introduces the definition of Minimal Residual Disease (MRD) Testing, market overview.
Chapter 2: Global Minimal Residual Disease (MRD) Testing market size in revenue.
Chapter 3: Detailed analysis of Minimal Residual Disease (MRD) Testing company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Minimal Residual Disease (MRD) Testing in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Minimal Residual Disease (MRD) Testing Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Minimal Residual Disease (MRD) Testing Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Minimal Residual Disease (MRD) Testing Overall Market Size
2.1 Global Minimal Residual Disease (MRD) Testing Market Size: 2022 VS 2029
2.2 Global Minimal Residual Disease (MRD) Testing Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Minimal Residual Disease (MRD) Testing Players in Global Market
3.2 Top Global Minimal Residual Disease (MRD) Testing Companies Ranked by Revenue
3.3 Global Minimal Residual Disease (MRD) Testing Revenue by Companies
3.4 Top 3 and Top 5 Minimal Residual Disease (MRD) Testing Companies in Global Market, by Revenue in 2022
3.5 Global Companies Minimal Residual Disease (MRD) Testing Product Type
3.6 Tier 1, Tier 2 and Tier 3 Minimal Residual Disease (MRD) Testing Players in Global Market
3.6.1 List of Global Tier 1 Minimal Residual Disease (MRD) Testing Companies
3.6.2 List of Global Tier 2 and Tier 3 Minimal Residual Disease (MRD) Testing Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Minimal Residual Disease (MRD) Testing Market Size Markets, 2022 & 2029
4.1.2 Flow Cytometry
4.1.3 Polymerase Chain Reaction
4.1.4 Next-generation Sequencing
4.1.5 Liquid Biopsies
4.2 By Type – Global Minimal Residual Disease (MRD) Testing Revenue & Forecasts
4.2.1 By Type – Global Minimal Residual Disease (MRD) Testing Revenue, 2018-2023
4.2.2 By Type – Global Minimal Residual Disease (MRD) Testing Revenue, 2024-2029
4.2.3 By Type – Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Minimal Residual Disease (MRD) Testing Market Size, 2022 & 2029
5.1.2 Specialty Clinics
5.1.3 Hospitals
5.1.4 Research Institutions
5.2 By Application – Global Minimal Residual Disease (MRD) Testing Revenue & Forecasts
5.2.1 By Application – Global Minimal Residual Disease (MRD) Testing Revenue, 2018-2023
5.2.2 By Application – Global Minimal Residual Disease (MRD) Testing Revenue, 2024-2029
5.2.3 By Application – Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Minimal Residual Disease (MRD) Testing Market Size, 2022 & 2029
6.2 By Region – Global Minimal Residual Disease (MRD) Testing Revenue & Forecasts
6.2.1 By Region – Global Minimal Residual Disease (MRD) Testing Revenue, 2018-2023
6.2.2 By Region – Global Minimal Residual Disease (MRD) Testing Revenue, 2024-2029
6.2.3 By Region – Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.3.2 US Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.3.3 Canada Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.3.4 Mexico Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.4.2 Germany Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.3 France Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.4 U.K. Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.5 Italy Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.6 Russia Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.7 Nordic Countries Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.4.8 Benelux Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.5.2 China Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.3 Japan Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.4 South Korea Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.5 Southeast Asia Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.5.6 India Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.6.2 Brazil Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.6.3 Argentina Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Minimal Residual Disease (MRD) Testing Revenue, 2018-2029
6.7.2 Turkey Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7.3 Israel Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7.4 Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
6.7.5 UAE Minimal Residual Disease (MRD) Testing Market Size, 2018-2029
7 Minimal Residual Disease (MRD) Testing Companies Profiles
7.1 Sysmex Corporation
7.1.1 Sysmex Corporation Company Summary
7.1.2 Sysmex Corporation Business Overview
7.1.3 Sysmex Corporation Minimal Residual Disease (MRD) Testing Major Product Offerings
7.1.4 Sysmex Corporation Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.1.5 Sysmex Corporation Key News & Latest Developments
7.2 Natera
7.2.1 Natera Company Summary
7.2.2 Natera Business Overview
7.2.3 Natera Minimal Residual Disease (MRD) Testing Major Product Offerings
7.2.4 Natera Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.2.5 Natera Key News & Latest Developments
7.3 Asuragen
7.3.1 Asuragen Company Summary
7.3.2 Asuragen Business Overview
7.3.3 Asuragen Minimal Residual Disease (MRD) Testing Major Product Offerings
7.3.4 Asuragen Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.3.5 Asuragen Key News & Latest Developments
7.4 Quest Diagnostics
7.4.1 Quest Diagnostics Company Summary
7.4.2 Quest Diagnostics Business Overview
7.4.3 Quest Diagnostics Minimal Residual Disease (MRD) Testing Major Product Offerings
7.4.4 Quest Diagnostics Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.4.5 Quest Diagnostics Key News & Latest Developments
7.5 Mission Bio
7.5.1 Mission Bio Company Summary
7.5.2 Mission Bio Business Overview
7.5.3 Mission Bio Minimal Residual Disease (MRD) Testing Major Product Offerings
7.5.4 Mission Bio Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.5.5 Mission Bio Key News & Latest Developments
7.6 LabCorp
7.6.1 LabCorp Company Summary
7.6.2 LabCorp Business Overview
7.6.3 LabCorp Minimal Residual Disease (MRD) Testing Major Product Offerings
7.6.4 LabCorp Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.6.5 LabCorp Key News & Latest Developments
7.7 Guardant Health
7.7.1 Guardant Health Company Summary
7.7.2 Guardant Health Business Overview
7.7.3 Guardant Health Minimal Residual Disease (MRD) Testing Major Product Offerings
7.7.4 Guardant Health Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.7.5 Guardant Health Key News & Latest Developments
7.8 NeoGenomics Laboratories
7.8.1 NeoGenomics Laboratories Company Summary
7.8.2 NeoGenomics Laboratories Business Overview
7.8.3 NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Major Product Offerings
7.8.4 NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.8.5 NeoGenomics Laboratories Key News & Latest Developments
7.9 ARUP Laboratories
7.9.1 ARUP Laboratories Company Summary
7.9.2 ARUP Laboratories Business Overview
7.9.3 ARUP Laboratories Minimal Residual Disease (MRD) Testing Major Product Offerings
7.9.4 ARUP Laboratories Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.9.5 ARUP Laboratories Key News & Latest Developments
7.10 NeoGenomics , Inc
7.10.1 NeoGenomics , Inc Company Summary
7.10.2 NeoGenomics , Inc Business Overview
7.10.3 NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Major Product Offerings
7.10.4 NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.10.5 NeoGenomics , Inc Key News & Latest Developments
7.11 Opko Health
7.11.1 Opko Health Company Summary
7.11.2 Opko Health Business Overview
7.11.3 Opko Health Minimal Residual Disease (MRD) Testing Major Product Offerings
7.11.4 Opko Health Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.11.5 Opko Health Key News & Latest Developments
7.12 Bio-Rad Laboratories
7.12.1 Bio-Rad Laboratories Company Summary
7.12.2 Bio-Rad Laboratories Business Overview
7.12.3 Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Major Product Offerings
7.12.4 Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Revenue in Global Market (2018-2023)
7.12.5 Bio-Rad Laboratories Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Minimal Residual Disease (MRD) Testing Market Opportunities & Trends in Global Market
Table 2. Minimal Residual Disease (MRD) Testing Market Drivers in Global Market
Table 3. Minimal Residual Disease (MRD) Testing Market Restraints in Global Market
Table 4. Key Players of Minimal Residual Disease (MRD) Testing in Global Market
Table 5. Top Minimal Residual Disease (MRD) Testing Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Minimal Residual Disease (MRD) Testing Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Minimal Residual Disease (MRD) Testing Revenue Share by Companies, 2018-2023
Table 8. Global Companies Minimal Residual Disease (MRD) Testing Product Type
Table 9. List of Global Tier 1 Minimal Residual Disease (MRD) Testing Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Minimal Residual Disease (MRD) Testing Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Minimal Residual Disease (MRD) Testing Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Minimal Residual Disease (MRD) Testing Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Minimal Residual Disease (MRD) Testing Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Minimal Residual Disease (MRD) Testing Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Minimal Residual Disease (MRD) Testing Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Minimal Residual Disease (MRD) Testing Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2024-2029
Table 30. Sysmex Corporation Company Summary
Table 31. Sysmex Corporation Minimal Residual Disease (MRD) Testing Product Offerings
Table 32. Sysmex Corporation Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 33. Sysmex Corporation Key News & Latest Developments
Table 34. Natera Company Summary
Table 35. Natera Minimal Residual Disease (MRD) Testing Product Offerings
Table 36. Natera Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 37. Natera Key News & Latest Developments
Table 38. Asuragen Company Summary
Table 39. Asuragen Minimal Residual Disease (MRD) Testing Product Offerings
Table 40. Asuragen Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 41. Asuragen Key News & Latest Developments
Table 42. Quest Diagnostics Company Summary
Table 43. Quest Diagnostics Minimal Residual Disease (MRD) Testing Product Offerings
Table 44. Quest Diagnostics Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 45. Quest Diagnostics Key News & Latest Developments
Table 46. Mission Bio Company Summary
Table 47. Mission Bio Minimal Residual Disease (MRD) Testing Product Offerings
Table 48. Mission Bio Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 49. Mission Bio Key News & Latest Developments
Table 50. LabCorp Company Summary
Table 51. LabCorp Minimal Residual Disease (MRD) Testing Product Offerings
Table 52. LabCorp Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 53. LabCorp Key News & Latest Developments
Table 54. Guardant Health Company Summary
Table 55. Guardant Health Minimal Residual Disease (MRD) Testing Product Offerings
Table 56. Guardant Health Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 57. Guardant Health Key News & Latest Developments
Table 58. NeoGenomics Laboratories Company Summary
Table 59. NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Product Offerings
Table 60. NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 61. NeoGenomics Laboratories Key News & Latest Developments
Table 62. ARUP Laboratories Company Summary
Table 63. ARUP Laboratories Minimal Residual Disease (MRD) Testing Product Offerings
Table 64. ARUP Laboratories Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 65. ARUP Laboratories Key News & Latest Developments
Table 66. NeoGenomics , Inc Company Summary
Table 67. NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Product Offerings
Table 68. NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 69. NeoGenomics , Inc Key News & Latest Developments
Table 70. Opko Health Company Summary
Table 71. Opko Health Minimal Residual Disease (MRD) Testing Product Offerings
Table 72. Opko Health Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 73. Opko Health Key News & Latest Developments
Table 74. Bio-Rad Laboratories Company Summary
Table 75. Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Product Offerings
Table 76. Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Revenue (US$, Mn) & (2018-2023)
Table 77. Bio-Rad Laboratories Key News & Latest Developments
List of Figures
Figure 1. Minimal Residual Disease (MRD) Testing Segment by Type in 2022
Figure 2. Minimal Residual Disease (MRD) Testing Segment by Application in 2022
Figure 3. Global Minimal Residual Disease (MRD) Testing Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Minimal Residual Disease (MRD) Testing Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Minimal Residual Disease (MRD) Testing Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Minimal Residual Disease (MRD) Testing Revenue in 2022
Figure 8. By Type - Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 9. By Application - Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 10. By Type - Global Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 12. By Application - Global Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 14. By Region - Global Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 15. By Country - North America Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 16. US Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 20. Germany Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 21. France Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 28. China Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 32. India Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 34. Brazil Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Minimal Residual Disease (MRD) Testing Revenue Market Share, 2018-2029
Figure 37. Turkey Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Minimal Residual Disease (MRD) Testing Revenue, (US$, Mn), 2018-2029
Figure 41. Sysmex Corporation Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Natera Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Asuragen Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Quest Diagnostics Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Mission Bio Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. LabCorp Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Guardant Health Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. ARUP Laboratories Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Opko Health Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • がん最小残存病変検査のグローバル市場展望 2023年-2029年：フローサイトメトリー、ポリメラーゼ連鎖反応（PCR）、次世代シーケンシング（NGS）、その他
  • 水中用レジオネラ菌検査のグローバル市場展望 2023年-2029年：尿抗原検査、ポリメラーゼ連鎖反応、直接蛍光抗体検査、その他
  • 体細胞由来マルチプレックス・アッセイのグローバル市場展望 2023年-2029年：フローサイトメトリー、蛍光検出、マルチプレックスリアルタイムPCR、その他
  • 食品安全診断機器のグローバル市場展望 2023年-2029年：クロマトグラフィーシステム、質量分析システム、ポリメラーゼ連鎖反応（PCR）システム、免疫測定システム、その他
  • 感染症分子診断のグローバル市場展望 2023年-2029年：ポリメラーゼ連鎖反応 PCR、分子ハイブリダイゼーション、バイオチップ、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC12397 )"最小残存病変（MRD）検査のグローバル市場展望 2023年-2029年：フローサイトメトリー、ポリメラーゼ連鎖反応、次世代シーケンシング、リキッドバイオプシー" (英文：Minimal Residual Disease (MRD) Testing Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。